Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine established a dedicated Neuroendocrine Tumors Program and named Aman Chauhan as leader.
Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.
